RT Journal Article SR Electronic T1 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events JF Journal for ImmunoTherapy of Cancer JO J Immunother Cancer FD BMJ Publishing Group Ltd SP e002435 DO 10.1136/jitc-2021-002435 VO 9 IS 6 A1 Julie R Brahmer A1 Hamzah Abu-Sbeih A1 Paolo Antonio Ascierto A1 Jill Brufsky A1 Laura C Cappelli A1 Frank B Cortazar A1 David E Gerber A1 Lamya Hamad A1 Eric Hansen A1 Douglas B Johnson A1 Mario E Lacouture A1 Gregory A Masters A1 Jarushka Naidoo A1 Michele Nanni A1 Miguel-Angel Perales A1 Igor Puzanov A1 Bianca D Santomasso A1 Satish P Shanbhag A1 Rajeev Sharma A1 Dimitra Skondra A1 Jeffrey A Sosman A1 Michelle Turner A1 Marc S Ernstoff YR 2021 UL http://jitc.bmj.com/content/9/6/e002435.abstract AB Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.